Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function

European Heart Journal

Volumn 19, Issue 3, 1998, Pages 402-410

  Båvenholm, Peter ^a   De Faire, U ^a   Landou, C ^a   Efendic, S ^a   Nilsson, J ^b   Wiman, B ^a   Hamsten, A ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Coronary angiography; Glucose; Insulin; Lipoproteins; Myocardial infarction; Plamsinogen activator inhibitor 1

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FIBRINOLYSIS; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; FIBRINOLYSIS; HEMOSTASIS; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; LIPOPROTEINS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032032320     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0752     Document Type: Article

References (47)

1. [1] Båvenholm P, Proudler A, Tornvall P et al. Insulin, intact and split proinsulin and coronary artery disease in young men. Circulation 1995; 9: 1422-9.
2. [2] Båvenholm P, Proudler A, Silveira A et al. Relationships of insulin and intact and split proinsulin to haemostatic function in men with and without coronary artery disease. Thromb Haemost 1995; 73: 568-75.
3. [3] Reaven GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
4. [4] Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
5. [5] Hamsten A, Walldius S, Dahlén G, Johansson B, de Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986; 59: 223-35.
6. [6] Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988; 260: 1917-21.
7. [7] Tornvall P, Båvenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically-defined coronary artery disease in young patients with myocardial infarction. Circulation 1993; 88: 2180-9.
8. [8] Hamsten A, Blombäck B, Wiman B et al. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 58-66.
9. [9] Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
10. [10] Manolio TA, Savage PJ, Burke GL et al. Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Arteriosclerosis 1990; 10: 430-6.
11. [11] Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance. The Whitehall Study. Lancet 1980; i: 154-60.
12. [12] Moss SE, Klein R, Klein BEK, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473-9.
13. [13] Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
14. [14] Malmberg K, Båvenholm P, Hamsten A. Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age. J Am Coll Cardiol 1994; 24: 592-9.
15. [15] Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. An angiographic evaluation of the effects of Bezafibrate on the progression of coronary artery disease in young male postinfarction patients. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Lancet 1996; 347: 849-53.
16. [16] Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
17. [17] Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Stanley P, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary by-pass grafts: Lipid and nonlipid factors. Circulation 1990; 81: 470-6.
18. [18] Hodis HN, Mack WJ, Azen SP et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42-9.
19. [19] Krauss RM, Williams PT, Brensike J et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; ii: 62-6.
20. [20] Hamsten A, Eféndic S, Walldius G, Szamosi A, de Faire U. Glucose tolerance and insulin response to glucose in non-diabetic young male survivors of myocardial infarction. Am Heart J 1987; 113: 917-27.
21. [21] Cerasi E, Luft R. The plasma insulin response to glucose infusion in healthy subjects and diabetes mellitus. Acta Endocrinol 1967; 55: 278-304.
22. [22] Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963; 88: 137-146.
23. [23] Carlsson K. Lipoprotein fractionation. J Clin Pathol 1973; 5: 32-7.
24. [24] Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970; 43: 891-915.
25. [25] Chmielewska J, Rãnby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36.
26. [26] Hamsten A, Walldius G, Szamosi A, Dahlén G, de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 1986; 73: 1097-1110.
27. [27] Austen WG, Edwards JE, Frye RL et al. AHA Committee Report: A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for grading of coronary artery disease, council on cardiovascular surgery, American Heart Association. Circulation 1975; 51: 7.
28. [28] Nikkilä EA, Viikinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br Med J 1984; 289: 220-3.
29. [29] Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-6.
30. [30] Austin MA, King M-C, Vranizan KM, Krauss RM.Atherogenic lipoprotein phenotype. A proposed marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
31. [31] Båvenholm, P, Karpe F, Proudler A, Tornvall P, Crook D, Hamsten A. Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype. Metabolism 1995; 44: 1481-8.
32. [32] Philips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993; 88: 2762-70.
33. [33] Tamura A, Watanabe T, Mikuriya Y, Nasu M. Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J 1995; 74: 365-9.
34. [34] Welborn TA, Wearne K. Coronary heart disease and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-60.
35. [35] Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care 1979; 2: 131-41.
36. [36] Pyörälä K, Savolainen S, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki policeman study population. Acta Med Scand 1985; 701: 38-52.
37. [37] Malmberg K, Rydén L, Eféndic S et al. A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI). J Am Coll Cardiol 1995; 26: 57-65.
38. [38] Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
39. [39] Kooistra T, Bosnia PJ, Töns HAM, van der Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: Biosynthesis and mRNA levels are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989; 62: 723-8.
40. [40] Schneider DJ, Nordt TK, Sobel BE. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890-5.
41. [41] Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-8.
42. [42] Mussoni L, Mannucci L, Sirtori M et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
43. [43] Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator-inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
44. [44] Latron Y, Chautan M, Anfosso F et al. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-9.
45. [45] Schneiderman J, Sawdey MS, Keeton MR et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
46. [46] Eliasson B, Attvall S, Taskinen M-R, Smith U. The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Throm 1994; 14: 1946-50.
47. [47] Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989; 298: 1152-7.